Premium
Evaluation of transsphenoidal hypophysectomy in the management of patients with advanced malignant melanoma
Author(s) -
Lawson David H.,
Nixon Daniel W.,
Black Marcus L.,
Tindall George T.,
Barnes David A.,
Faraj Bahjat A.,
Ali Farouk M.,
Camp Ver M.,
Richmond Ann
Publication year - 1983
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19830415)51:8<1541::aid-cncr2820510831>3.0.co;2-s
Subject(s) - medicine , hypophysectomy , excretion , melanoma , metabolite , acromegaly , surgery , endocrinology , urology , growth hormone , hormone , cancer research
Transsphenoidal hypophysectomy was performed in 13 patients with advanced malignant melanoma. Although three minor responses were observed, there were no complete or partial responses. All three patients with bone pain had a decrease in discomfort lasting 1–2 months. All five patients with minor responses or stable disease had postoperative decreases in the excretion of the dihydroxyphenylalanine (DOPA) metabolite 3‐O‐methyldopamine; all but one patient with clinical progression had postoperative increases in excretion. Average survival of those whose postoperative excretion fell (143+ days; range, 60–217+) was significantly longer ( P < 0.004) than that of those whose postsurgical values rose (30 days; range, 15–58).